BidaskClub downgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a strong sell rating in a research report released on Friday.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 13th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $41.00 target price on the stock in a report on Tuesday, July 24th. SunTrust Banks started coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 5th. They issued a buy rating on the stock. Guggenheim started coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 17th. They issued a buy rating on the stock. Finally, Cantor Fitzgerald started coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, September 6th. They issued a buy rating and a $53.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals has an average rating of Buy and an average target price of $47.55.

NASDAQ DCPH traded down $4.97 during trading hours on Friday, hitting $22.26. The company’s stock had a trading volume of 1,036,294 shares, compared to its average volume of 263,751. Deciphera Pharmaceuticals has a twelve month low of $15.15 and a twelve month high of $45.61. The firm has a market capitalization of $1.03 billion and a P/E ratio of -7.44. The company has a debt-to-equity ratio of 0.05, a current ratio of 18.44 and a quick ratio of 18.44.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. Sell-side analysts expect that Deciphera Pharmaceuticals will post -2.61 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of DCPH. Redmile Group LLC raised its holdings in shares of Deciphera Pharmaceuticals by 79.9% during the second quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after acquiring an additional 655,800 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth $21,989,000. Orbimed Advisors LLC raised its holdings in shares of Deciphera Pharmaceuticals by 30.8% during the second quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after acquiring an additional 472,800 shares during the period. FMR LLC raised its holdings in shares of Deciphera Pharmaceuticals by 33.5% during the second quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after acquiring an additional 296,571 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth $9,953,000. Institutional investors own 53.52% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Featured Article: Why do company’s buyback their stock?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.